Yousif Capital Management LLC Acquires 697 Shares of Corcept Therapeutics Incorporated $CORT

Yousif Capital Management LLC increased its holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT) by 2.6% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 27,898 shares of the biotechnology company’s stock after purchasing an additional 697 shares during the period. Yousif Capital Management LLC’s holdings in Corcept Therapeutics were worth $2,048,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of CORT. Vanguard Personalized Indexing Management LLC increased its position in Corcept Therapeutics by 14.7% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 10,110 shares of the biotechnology company’s stock valued at $742,000 after acquiring an additional 1,299 shares during the last quarter. Oak Ridge Investments LLC increased its position in Corcept Therapeutics by 13.6% during the second quarter. Oak Ridge Investments LLC now owns 23,323 shares of the biotechnology company’s stock valued at $1,712,000 after acquiring an additional 2,784 shares during the last quarter. Concurrent Investment Advisors LLC increased its position in Corcept Therapeutics by 3.4% during the second quarter. Concurrent Investment Advisors LLC now owns 6,175 shares of the biotechnology company’s stock valued at $453,000 after acquiring an additional 205 shares during the last quarter. Maryland State Retirement & Pension System increased its position in Corcept Therapeutics by 18.7% during the second quarter. Maryland State Retirement & Pension System now owns 32,305 shares of the biotechnology company’s stock valued at $2,371,000 after acquiring an additional 5,091 shares during the last quarter. Finally, Louisiana State Employees Retirement System increased its position in Corcept Therapeutics by 0.5% during the second quarter. Louisiana State Employees Retirement System now owns 44,100 shares of the biotechnology company’s stock valued at $3,237,000 after acquiring an additional 200 shares during the last quarter. Institutional investors own 93.61% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on CORT shares. Canaccord Genuity Group reiterated a “buy” rating and set a $140.00 price objective on shares of Corcept Therapeutics in a research report on Thursday, September 25th. Weiss Ratings restated a “hold (c)” rating on shares of Corcept Therapeutics in a report on Wednesday, October 8th. Wall Street Zen cut shares of Corcept Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday. HC Wainwright restated a “buy” rating and issued a $145.00 price target on shares of Corcept Therapeutics in a report on Friday, October 10th. Finally, Piper Sandler cut their price target on shares of Corcept Therapeutics from $131.00 to $121.00 and set an “overweight” rating on the stock in a report on Friday, August 1st. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Corcept Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $135.25.

Insider Buying and Selling

In related news, Director Daniel N. Swisher, Jr. sold 2,200 shares of the company’s stock in a transaction dated Friday, October 10th. The shares were sold at an average price of $87.54, for a total value of $192,588.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Joseph K. Belanoff sold 40,000 shares of the company’s stock in a transaction dated Wednesday, October 1st. The stock was sold at an average price of $85.08, for a total transaction of $3,403,200.00. Following the completion of the sale, the chief executive officer directly owned 2,781,370 shares of the company’s stock, valued at approximately $236,638,959.60. This trade represents a 1.42% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 292,451 shares of company stock valued at $21,850,930 over the last quarter. 20.80% of the stock is owned by company insiders.

Corcept Therapeutics Price Performance

NASDAQ:CORT opened at $78.69 on Friday. Corcept Therapeutics Incorporated has a 1-year low of $42.01 and a 1-year high of $117.33. The company has a 50-day moving average of $76.01 and a 200 day moving average of $73.04. The firm has a market cap of $8.29 billion, a PE ratio of 69.64 and a beta of 0.46.

Corcept Therapeutics (NASDAQ:CORT) last released its quarterly earnings data on Thursday, July 31st. The biotechnology company reported $0.29 earnings per share for the quarter, topping analysts’ consensus estimates of $0.23 by $0.06. Corcept Therapeutics had a net margin of 18.51% and a return on equity of 20.10%. The company had revenue of $194.43 million during the quarter, compared to analyst estimates of $199.40 million. During the same period in the prior year, the firm earned $0.32 earnings per share. The firm’s revenue for the quarter was up 18.7% compared to the same quarter last year. Corcept Therapeutics has set its FY 2025 guidance at EPS. Sell-side analysts anticipate that Corcept Therapeutics Incorporated will post 1.36 EPS for the current fiscal year.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.